Topical enviroxime against rhinovirus infection.

Abstract

Enviroxime, an inhibitor of rhinovirus replication, was studied in a double-blind, placebo-controlled trial with 99 volunteers. The efficacy of a nasal-spray formulation of enviroxime was tested as pretreatment or as postchallenge treatment for rhinovirus type 4 infection. In the regimens used, drug administration neither prevented infection nor reduced the frequency of specific colds. The mean concentration of enviroxime in nasal washes (12 h after a dose) differentiated two groups of responders. Those in whom the drug concentration exceeded 100 ng/ml had some benefits, although these were statistically insignificant.

• Authors: R A Levandowski, C T Pachucki, M Rubenis, G G Jackson
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 22 Issue 6 Pg. 1004-7 (Dec 1982) ISSN: 0066-4804 [Print] United States
• PMID: 6297380 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Aerosols
• Antibodies, Viral
• Antiviral Agents
• Benzimidazoles
• Oximes
• Sulfonamides
• viroxime

Topics

• Administration, Intranasal
• Adult
• Aerosols
• Antibodies, Viral (analysis)
• Antiviral Agents (administration & dosage, therapeutic use)
• Benzimidazoles (administration & dosage, therapeutic use)
• Common Cold (prevention & control)
• Double-Blind Method
• Female
• Humans
• Male
• Oximes
• Rhinovirus (immunology)
• Sulfonamides